UNSPSC 51401527: Ketazolam

This classification denotes a benzodiazepine with the molecular formula C20H17ClN2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 92A214MD7Y, chemically known as 11-chloro-8,12b-dihydro-2,8-dimethyl-12b-phenyl-4h-(1,3)oxazino(3,2-d)(1,4)benzodiazepine-4,7(6h)-dione but generally known as ketazolam, which bears US NIH Compound Identifier 33746. European Medicines Agency schedules Ketazolam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08368MIG.

UNSPSC 51401527 Ketazolam is a Commodity code representing pharmaceutical products that state and local governments procure for emergency medical response, public health initiatives, and broader pharmacy benefit programs. Recent solicitations show that issuing bodies are buying naloxone and related drug management systems, generic pharmaceuticals, and over-the-counter products through competitive bidding and cooperative purchasing mechanisms, though the mismatch between the code's nominal designation (ketazolam, a benzodiazepine) and actual recent opportunities suggests the code may be misapplied or reflects a broader pharmaceutical-procurement category in practice. Issuing bodies under this code include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, administered by the Minnesota Department of Administration's Office of State Procurement). The procurement approaches vary from traditional IFB and RFP mechanisms to exploratory Request for Information (RFI) phases designed to inform future contracting strategy.

Recent activity spans Florida and Minnesota, with Texas engaged in market intelligence gathering. Seminole County posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries to the county community health building, with a response deadline of July 26, 2023 (note: date appears inconsistent in source). The Texas HHS Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for implementing a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program, a preliminary intelligence phase preceding formal procurement. The Minnesota Multistate Cooperative Purchasing Alliance issued RFP S1070000015802 on January 20, 2026, to establish multiple contracts for generic pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026 and contract effectiveness set for July 1, 2026. Vendors responding to the Minnesota RFP must work through authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson), comply with cGMP and DSCSA requirements, maintain $5 million commercial general liability insurance, and accept a 3 percent administrative fee on contract purchases.